1. Home
  2. PFN vs PRME Comparison

PFN vs PRME Comparison

Compare PFN & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Income Strategy Fund II

PFN

PIMCO Income Strategy Fund II

HOLD

Current Price

$6.26

Market Cap

681.9M

Sector

Finance

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.13

Market Cap

553.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFN
PRME
Founded
N/A
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
681.9M
553.2M
IPO Year
2004
2022

Fundamental Metrics

Financial Performance
Metric
PFN
PRME
Price
$6.26
$3.13
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$7.56
AVG Volume (30 Days)
506.0K
2.5M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.18
EPS
N/A
N/A
Revenue
N/A
$4,632,000.00
Revenue This Year
N/A
$7.06
Revenue Next Year
N/A
$47.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
55.28
52 Week Low
$6.32
$2.67
52 Week High
$7.65
$6.94

Technical Indicators

Market Signals
Indicator
PFN
PRME
Relative Strength Index (RSI) 16.91 56.17
Support Level N/A $3.14
Resistance Level $7.18 $3.72
Average True Range (ATR) 0.08 0.22
MACD -0.04 0.00
Stochastic Oscillator 0.00 63.44

Price Performance

Historical Comparison
PFN
PRME

About PFN PIMCO Income Strategy Fund II

PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in different range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: